Search

Author/Creator Saura, C

2. 84TiPHER-Seq: A blood-based genomic screening study to identify HER2 mutation-positive patients for enrollment into clinical trials with the pan-HER inhibitor neratinib. (13th May 2019)

Authors:
Tomasevic, Z; Smyth, L M; Saura, C; Boni, V; Garcia-Sáenz, J Á; Prat, A; Eli, L; Garza, S J; Lalani, A S; Crown, J P
Journal:
Annals of oncology
Issue:
Volume 30(2019)Supplement 3
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. 92PVall d'Hebron Institute of Oncology (VHIO) immuno-oncology prognostic index (VIO): A new tool for improved patient (pt) selection in phase I (Ph1) trials with immune checkpoint inhibitors (ICI). (23rd October 2018)

Authors:
Hierro, C; Matos, I; Martin-Liberal, J; Ochoa De Olza Amat, M; Felip, E; Costa Rivas, M; Vieito Villar, M; Brana, I; Azaro, A; Perez-Gago, M C; Gros, A; Carles, J; Oaknin, A; Macarulla, T; Saura, C; pardo, N; Muñoz-Couselo, E; Tabernero, J; Dienstmann, R; Garralda, E
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle. (30th April 2018)

Authors:
Mattos-Arruda, L De; Weigelt, B; Cortes, J; Won, H H; Ng, C K Y; Nuciforo, P; Bidard, F -C; Aura, C; Saura, C; Peg, V; Piscuoglio, S; Oliveira, M; Smolders, Y; Patel, P; Norton, L; Tabernero, J; Berger, M F; Seoane, J; Reis-Filho, J S
Journal:
Annals of oncology
Issue:
Volume 29:Number 11(2018)
Page Start:
2268
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer. (30th May 2019)

Authors:
Oliveira, M; Saura, C; Nuciforo, P; Calvo, I; Andersen, J; Passos-Coelho, J L; Gil Gil, M; Bermejo, B; Patt, D A; Ciruelos, E; de la Peña, L; Xu, N; Wongchenko, M; Shi, Z; Singel, S M; Isakoff, S J
Journal:
Annals of oncology
Issue:
Volume 30:Number 8(2019)
Page Start:
1289
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). (31st January 2019)

Authors:
Condorelli, R; Mosele, F; Verret, B; Bachelot, T; Bedard, P L; Cortes, J; Hyman, D M; Juric, D; Krop, I; Bieche, I; Saura, C; Sotiriou, C; Cardoso, F; Loibl, S; Andre, F; Turner, N C
Journal:
Annals of oncology
Issue:
Volume 30:Number 3(2019)
Page Start:
365
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer. (4th April 2018)

Authors:
Cruz, C; Castroviejo-Bermejo, M; Gutiérrez-Enríquez, S; Llop-Guevara, A; Ibrahim, Y H; Gris-Oliver, A; Bonache, S; Morancho, B; Bruna, A; Rueda, O M; Lai, Z; Polanska, U M; Jones, G N; Kristel, P; de Bustos, L; Guzman, M; Rodríguez, O; Grueso, J; Montalban, G; Caratú, G
Journal:
Annals of oncology
Issue:
Volume 29:Number 5(2018)
Page Start:
1203
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗